Public hearings set in Southwest Missouri over Liberty Utilities rate hike
Liberty is looking for an increase of $152.8 million per year from rate revenues and to raise the monthly fixed residential customer charge from $13 to $16, PSC says.
The hearings will consist of a public information and Q&A session, followed by the Commission taking public comments. Those interested in attending are encouraged to go to the meeting location closest to their service area.
Missouri Public Service Commission investigating Liberty Utilities billing
The in-person public hearing schedule is as follows:
July 21 at 6 p.m.: Joplin, Missouri Southern State University, Corley Hall, 3950 Newman Road
July 22 at noon: Nixa, City Council Chambers, 715 West Mount Vernon Street
July 22 at 6 p.m.: Bolivar, Southwest Baptist University, McClelland Joe Roberts Room, 1600 University Avenue
July 23 at noon: Branson, City Council Chambers, 110 West Maddux Street
July 24 at noon: Aurora, Recreation Center, 126 West Hadley Street
There will also be two virtual local public hearings on July 23 at 6 p.m. and July 25 at noon. To attend the hearing by telephone, you can call toll-free at 1-855-718-6621 and enter the access code 2861 936 9973 when prompted for the July 23 meeting and access code 2866 586 9948 when prompted for the July 25 hearing, then press #. If prompted for a password, enter 0261.
To attend a virtual hearing online, visit webex.com or download the Cisco WebEx application on your mobile device, computer or tablet and join the meeting by the hearing time and entering the access code and password above.
Individuals who cannot make the hearings can also submit a written comment through the methods on the PSC website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 days ago
- Business Wire
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the second quarter 2025 and provided a business update. 'Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch,' said Chris Peetz, chief executive officer of Mirum. 'The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients than we initially projected, allowing us to raise guidance with confidence.' Peetz added, 'We are carrying that same momentum into our pipeline, where we are on course for three important late stage clinical milestones in 2026. Notably, the VISTAS study of volixibat in PSC will complete enrollment this quarter, and we plan to report topline data in the second quarter of next year.' Commercial: Raising full year revenue guidance to $490 to $510 million Second quarter 2025 global net product sales of $127.8 million. Second quarter 2025 LIVMARLI net product sales were $88.2 million, representing 87% growth over second quarter 2024 net product sales. LIVMARLI single oral tablet dose U.S. launch in June. Bile Acid Medicines second quarter 2025 net product sales were $39.6 million, representing 30% growth over second quarter 2024 net product sales. Pipeline: Advancing toward multiple 2026 milestones Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected in the second quarter of 2026. Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026. LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026. Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in the fourth quarter of 2025. Corporate and Financial: Strong balance sheet and financial independence Total revenue for the quarter ended June 30, 2025, was $127.8 million compared to $77.9 million for the quarter ended June 30, 2024. Total operating expenses were $132.8 million for the quarter ended June 30, 2025, compared to $102.1 million for the quarter ended June 30, 2024. Total operating expenses for the quarter ended June 30, 2025, included $24.5 million of non-cash stock-based compensation, intangible amortization, and other non-cash expenses compared to $17.7 million for the quarter ended June 30, 2024. As of June 30, 2025, Mirum had unrestricted cash, cash equivalents, and investments of $321.7 million compared to $292.8 million as of December 31, 2024. Business Update Conference Call Mirum will host a conference call today, August 6 th at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details: Conference Call Details: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Access Code: 448461 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets LIVMARLI® (maralixibat) is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum's clinical trials section on the company's website. IMPORTANT SAFETY INFORMATION Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein. LIVMARLI can cause side effects, including Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal. Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you. A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects. EU SmPC Canadian Product Monograph About Volixibat Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (PSC) (VISTAS study), and primary biliary cholangitis (PBC) (VANTAGE study). In 2024, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate. Volixibat has been granted breakthrough therapy designation for the treatment of PBC. About CHOLBAM® (cholic acid) capsules The FDA approved CHOLBAM (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. The effectiveness of CHOLBAM has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. An estimated 200 to 300 patients are current candidates for therapy. CHOLBAM® (cholic acid) Indication CHOLBAM is a bile acid indicated for Treatment of bile acid synthesis disorders due to single enzyme defects. Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption. LIMITATIONS OF USE The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment. Concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate CHOLBAM overdose. Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis. ADVERSE REACTIONS The most common adverse reactions (≥1%) are diarrhea, reflux esophagitis, malaise, jaundice, skin lesion, nausea, abdominal pain, intestinal polyp, urinary tract infection, and peripheral neuropathy. Please see full Prescribing Information for additional Important Safety Information. About CTEXLI™ (chenodiol) tablets CTEXLI™ (chenodiol) tablets is FDA-approved for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Chenodiol is another name for chenodeoxycholic acid (CDCA). CDCA is a naturally occurring bile acid that was originally approved for the treatment of people with radiolucent stones in the gallbladder. CTEXLI was evaluated as part of the Phase 3 RESTORE study, the first and only clinical trial for CTX. CTX is a rare progressive disease that can affect the brain, spinal cord, tendons, eyes and arteries. IMPORTANT SAFETY INFORMATION CTEXLI can cause side effects, including: Liver Injury: You will need to undergo laboratory testing before starting and while taking CTEXLI to check your liver function. Changes in certain liver tests may occur during treatment and may be a sign of liver injury. This can be serious. Stop taking CTEXLI immediately and tell your healthcare provider right away if you get any signs or symptoms of liver problems, including, stomach (abdomen) pain, bruising, dark-colored urine, feeling tired (fatigue), bleeding, yellowing of the skin and eyes, nausea, and itching. Most Common Side Effects: Diarrhea, headache, stomach pain, constipation, high blood pressure, muscular weakness, and upper respiratory tract infection. Tell your healthcare provider about all the medications that you take, as CTEXLI may interact with other medicines. US Prescribing Information About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X). Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, continued positive commercial results for our approved medicines, including continued financial growth, the potential achievement of our yearly financial guidance, continued strong execution across our approved medicines and pipeline, the initiation, results, enrollment, conduct and progress of our ongoing and planned studies for our product candidates, the timing and results of interim analyses of, and topline data for, our ongoing studies and the regulatory approval path for our product candidates in any indication or any specific territory. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'expected,' 'will,' 'could,' 'would,' 'guidance,' 'potential,' 'continue' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum's Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Mirum Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (Unaudited) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 228,122 $ 222,503 Short-term investments 76,430 57,812 Accounts receivable 106,836 78,286 Inventory 22,941 22,403 Prepaid expenses and other current assets 19,069 11,784 Total current assets 453,398 392,788 Restricted cash 480 425 Long-term investments 17,112 12,526 Intangible assets, net 237,870 249,819 Other noncurrent assets 16,965 15,196 Total assets $ 725,825 $ 670,754 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 17,657 $ 14,618 Accrued expenses and other current liabilities 127,139 111,933 Total current liabilities 144,796 126,551 Operating lease liabilities, noncurrent 7,884 7,972 Convertible notes payable, net, noncurrent 308,933 308,082 Other liabilities 9,054 2,509 Total liabilities 470,667 445,114 Commitments and contingencies Stockholders' equity: Preferred stock — — Common stock 5 5 Additional paid-in capital 919,520 870,189 Accumulated deficit (664,719 ) (644,181 ) Accumulated other comprehensive income (loss) 352 (373 ) Total stockholders' equity 255,158 225,640 Total liabilities and stockholders' equity $ 725,825 $ 670,754 Expand
Yahoo
6 days ago
- Yahoo
Spire Inc (SR) Q3 2025 Earnings Call Highlights: Strategic Acquisitions and Revenue Growth Amid ...
Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Spire Inc (NYSE:SR) reported adjusted earnings of $0.01 per share, an improvement from a loss of $0.14 per share a year ago. The company announced a strategic acquisition of Piedmont Natural Gas Tennessee business, expanding its regulated utility footprint. A unanimous stipulation and agreement for an annual revenue increase of $210 million was filed, pending approval by the Missouri Public Service Commission. Spire Inc (NYSE:SR) reaffirmed its long-term EPS growth target of 5 to 7%, supported by a $7.4 billion capital investment plan. The expansion of Spire Storage West was completed, with returns exceeding expectations, contributing to strong earnings growth in the midstream segment. Negative Points The gas utility segment reported an adjusted loss of $10 million in the third quarter, despite a slight improvement from the prior year. Higher operating costs were noted in the midstream segment due to increased activity. The company faces uncertainties and risks that may affect future performance, as outlined in their SEC filings. Spire Inc (NYSE:SR) is pursuing a permanent capital structure for the acquisition, which includes a balanced mix of debt, equity, and hybrid securities, indicating potential financial strain. The company is evaluating the sale of non-utility assets, such as natural gas storage facilities, as a potential source of funds, which could impact future revenue streams. Q & A Highlights Warning! GuruFocus has detected 14 Warning Signs with SR. Q: Is the target of 15 to 16% still the right framework to think about going forward? A: Yes, those targets are still valid, though there might be a slight delay in reaching them due to the acquisition transition period. (Adam Wooder, CFO) Q: How much of the midstream results are due to the expansion of storage, and is this quarter a reasonable run rate for the business? A: About 90% of the increase in midstream is attributable to storage, with a 75% to 25% split between storage and pipeline on a net income basis. (Adam Wooder, CFO) Q: Are there opportunities for capacity on various pipelines in Missouri given the trends and comments from electric utilities? A: Yes, there are opportunities due to the IRPs associated with electric businesses, and we have low CapEx needs to serve these opportunities. (Scott Doyle, CEO) Q: Can we expect the same strong marketing results in the fourth quarter, or were they pulled into the third quarter? A: The third quarter was strong, and while the fourth quarter tends to be quieter, we feel good about the operations and targets for year-end. (Adam Wooder, CFO) Q: Does the long-term 5 to 7% growth rate include impacts from the Missouri rate case settlement and future test year legislation? A: The 5 to 7% growth rate is based on capital deployment, with some catch-up expected from Missouri recovery, but it primarily focuses on long-term rate-based growth. (Adam Wooder, CFO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Wire
01-08-2025
- Business Wire
Maryland American Water Files Rate Request Driven by $22 Million of Investment Over Last Seven Years
BEL AIR, Md.--(BUSINESS WIRE)--Maryland American Water filed a request today with the Maryland Public Service Commission (PSC) for new rates, reflecting $22 million of water system investments since the company's last rate request. The request reinforces the company's commitment to replacing aging infrastructure and continuing to provide high-quality water service in compliance with environmental regulations for the benefit of customers. 'Our commitment to long-term investments in our water systems helps ensure we deliver the high level of service our customers deserve and expect,' said Laura Runkle, President of Maryland American Water. 'These ongoing investments are vital for providing safe, clean, reliable and affordable service to the communities we serve and demonstrate our dedication to the public health and safety of those communities.' In today's filing, Maryland American Water's proposed rates include a two-tiered rate structure, with lower rates for the first 2,000 gallons to promote affordability for lower-usage customers. If the company's proposed two-tiered rates are approved, the monthly water bill for residential customers in the Town of Bel Air using 2,000 gallons per month would increase by approximately $6, and customers using 4,000 gallons per month would see an increase of approximately $29. Monthly water bills for residential customers in the company's Severn District would increase approximately $20 per month. The company's last rate adjustment was in 2019. Maryland American Water also offers bill paying assistance programs that include payment plans, budget billing and, for income-eligible customers, the company's H2O Help to Others customer assistance program. More information can be found by clicking the Customer Assistance Program link under Customer Service & Billing on the company's website. The proposed rates are a request only and are not final until authorized by the PSC, which conducts a thorough review of the company's financial and operational data. Once a final decision has been made, customers will receive information regarding new rates in the mail and on the company's website. New rates are not expected to be effective until March 2026. Customers can participate through written comments, attendance at public comment hearings, and consumer advocacy organizations that participate in the proceedings. For more information on the company's rate proposal and to learn how customers may participate in this process, visit and select 'Your Water Rates' under the Customer Service & Billing menu. About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. About Maryland American Water Maryland American Water, a subsidiary of American Water, provides safe, clean, reliable and affordable water services to approximately 24,000 people. AWK-IR
